Sigvaris USA, part of an internationally active medical device group, has launched a new, therapeutic compression sock option for patients with diabetes.

Uniquely constructed with patented drirelease yarns and an embedded FreshGuard technology treatment, Sigvaris Eversoft diabetic socks keeps away moisture and prevents odour, thus reducing friction against the skin and lowering the risk of infection, according to a press release.

The therapeutic socks provide 8-15mmHg of graduated compression that improves circulation. A Sigvaris flat toe seam design minimizes irritation, and a stretchable top band further enhances wearing comfort. With the launch of the new Eversoft diabetic socks, physicians will now be able to determine whether a patient needs a light (8-15mmHg) or a moderate (18-25mmHg) compression therapy level and be able to prescribe the Sigvaris compression therapy that best suits the needs of each individual patient.

David Rosenberg, director of marketing for Sigvaris North America said, “By creating the most innovative products with the finest textiles available, Sigvaris has quickly become a trusted name in compression therapy for diabetic patients.”

Sigvaris focuses on the development, production, and distribution of medical compression garments, including hosiery and socks. With distribution in more than 60 countries on six continents, the company is recognized as a global industry leader in the area of compression therapy for the management of chronic venous disorders. (GK)